Cancers, Vol. 12, Pages 1467: ImmunoPET in Multiple Myeloma —What? So What? Now What?

Cancers, Vol. 12, Pages 1467: ImmunoPET in Multiple Myeloma—What? So What? Now What? Cancers doi: 10.3390/cancers12061467 Authors: Clément Bailly Benjamin Chalopin Sébastien Gouard Thomas Carlier Patricia Remaud-Le Saëc Séverine Marionneau-Lambot Philippe Moreau Cyrille Touzeau Françoise Kraeber-Bodere Caroline Bodet-Milin Michel Chérel Despite constant progress over the past three decades, multiple myeloma (MM) is still an incurable disease, and the identification of new biomarkers to better select patients and adapt therapy is more relevant than ever. Recently, the introduction of therapeutic monoclonal antibodies (mAbs) (including direct-targeting mAbs and immune checkpoint inhibitors) appears to have changed the paradigm of MM management, emphasizing the opportunity to cure MM patients through an immunotherapeutic approach. In this context, immuno-positron emission tomography (immunoPET), combining the high sensitivity and resolution of a PET camera with the specificity of a radiolabelled mAb, holds the capability to cement this new treatment paradigm for MM patients. It has the potential to non-invasively monitor the distribution of therapeutic antibodies or directly monitor biomarkers on MM cells, and to allow direct observation of potential changes over time and in response to various therapeutic interventions. Tumor response could, in the future, be anticipated more effectively to provide individualized treatment plans tailored to p...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Perspective Source Type: research